Trust Point Inc. Decreases Position in Eli Lilly and Company (NYSE:LLY)

Trust Point Inc. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 29.0% in the 1st quarter, HoldingsChannel reports. The firm owned 2,855 shares of the company’s stock after selling 1,165 shares during the quarter. Trust Point Inc.’s holdings in Eli Lilly and Company were worth $2,358,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. FPC Investment Advisory Inc. boosted its holdings in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares during the period. Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $43,000. Prudent Man Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $48,000. Capital A Wealth Management LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth about $63,000. Finally, Bellwether Advisors LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth about $66,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on LLY shares. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their target price for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Finally, UBS Group dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Price Performance

LLY stock opened at $818.56 on Monday. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a 50-day moving average price of $775.43 and a 200 day moving average price of $801.69. The stock has a market cap of $775.78 billion, a PE ratio of 69.90, a P/E/G ratio of 1.40 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. During the same period in the prior year, the firm posted $2.58 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 45.2% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a dividend of $1.50 per share. The ex-dividend date was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.73%. Eli Lilly and Company’s payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.